High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?

Clinical Sarcoma Research

Stefano Ferrari³  Piero Picci⁴  Davide Maria Donati²  Emanuela Marchesi³  Manuela Cesari³  Emanuela Palmerini³  Marco Gambarotti⁴  Angelo Paolo Dei Tos¹  Anna Paioli³  Alberto Righi⁴ 

[1] Department of Pathology, Treviso Regional Hospital, Treviso, Italy;Department of Orthopaedic Oncology, Rizzoli Institute, Bologna, Italy;Department of Oncology, Rizzoli Institute, Bologna, Italy;Department of Pathology, Rizzoli Institute, Via di Barbiano 1/10, Bologna, 40136, Italy

关键词: Prognosis;    Chemotherapy;    High-grade;    Central;    Low-grade osteosarcoma;   

Others  :  1230349
DOI  :  10.1186/s13569-015-0038-7

 received in 2015-09-08, accepted in 2015-10-27,  发布年份 2015

【 摘 要 】

Background

High-grade foci (grade 3 according to Broder’s grading system) are sometimes detected in low-grade (grade 1 and 2) central osteosarcoma. The aim of this study was to retrospectively evaluate the clinical outcome in patients upgraded to high grade (grade 3) after a first diagnosis of low-grade osteosarcoma, following the detection of high-grade areas (grade 3) in the resected specimen.

Methods

Of the 132 patients with a diagnosis of low-grade central osteosarcoma at surgical biopsy at our Institute, 33 patients were considered eligible for the study.

Results

Median age was 37 (range 13–58 years). Location was in an extremity in 29 patients (88 %). Post-operative chemotherapy was given in 22 (67 %) patients. Follow-up data were available for all patients, with a median observation time of 115 months (range 4–322 months). After histological revision, areas of high-grade (grade 3) osteosarcoma accounting for less than 50 % of the tumor were found in 20 (61 %) patients, whereas the majority of the tumor was composed of a high-grade (grade 3) component in 13 (39 %) patients. In the 20 cases of low-grade osteosarcoma with high-grade foci (grade 3) in less than 50 % of the tumor, 9 patients did not receive adjuvant chemotherapy; only one of them died, of unrelated causes. In the adjuvant chemotherapy group (11 out of 20 patients), one patient developed multiple lung metastases and died of disease 39 months after the first diagnosis. In the other 13 cases of low-grade osteosarcoma with high-grade foci (grade 3) in more than 50 % of the tumor, 12 patients received adjuvant chemotherapy: 2 had recurrence, 4 developed multiple lung metastases and 3 died of disease. The only patient who did not receive chemotherapy is alive without disease 232 months after complete surgical remission.

Conclusion

Our data indicate that patients with a diagnosis of low-grade osteosarcoma where the high-grade (grade 3) component is lower than 50 % of the resected specimen, may not require chemotherapy, achieving high survival rates by means of complete surgical resection only.

【 授权许可】

   
2015 Righi et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]Unni KK. Osteosarcoma of bone. Churchill Livingstone, New York; 1988.
• [2]Grimer RJ, Hogendoorn PCW, Vanel D. Tumours of bone: introduction. In: World Health organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. 4th ed. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. IARC Press, Lyon; 2013: p.244-247.
• [3]Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20:137-139.
• [4]Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006; 125(4):555-581.
• [5]Inwards C, Squire J. Low-grade central osteosarcoma. In: World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. 4th ed. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. IARC Press, Lyon; 2013: p.281.
• [6]Bertoni F, Bacchini P, Fabbri N, Mercuri M, Picci P, Ruggieri T, Campanacci M. Low grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer. 1993; 71:338-345.
• [7]Kurt AM, Unni KK, McLeod RA, Pritchard DJ. Low-grade intraosseous osteosarcoma. Cancer. 1990; 65(6):1418-1428.
• [8]Schwab JH, Antonescu CR, Athanasian EA, Boland PJ, Healey JH, Morris CD. A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res. 2008; 466(6):1318-1322.
• [9]Wenger DE, Sundaram M, Unni KK, Janney CG, Merkel K. Microscopic correlation of radiographically disparate appearing well differentiated osteosarcoma. Skeletal Radiol. 2002; 31(8):488-492.
• [10]Ogose A, Hotta T, Emura I, Imaizumi S, Takeda M, Yamamura S. Repeated dedifferentiation of low-grade intraosseous osteosarcoma. Hum Pathol. 2000; 31:615-618.
• [11]Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012; 36:423-431.
• [12]Antonescu CR, Huvos AG. Low-grade osteogenic sarcoma arising in medullary and surface osseous locations. Am J Clin Pathol. 2000; 114:S90-S103.
• [13]Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014; 40:523-532.
• [14]Manoso MW, Healey JH, Boland PJ, Athanasian EA, Maki RG, Huvos AG, Morris CD. De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. Clin Orthop Relat Res. 2005; 438:110-115.
• [15]Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10:5-15.
• [16]Rubin BP, Antonescu CR, Gannon FH, Hunt JL, Inwards CY, Klein MJ, Kneisl JS, Montag AG, Peabody TD, Reith JD, Rosenberg AE, Krausz T. Protocol for the examination of specimens from patients with tumors of bone. Arch Pathol Lab Med. 2010; 134:e1-e7.
• [17]Kenan S, Ginat DT, Steiner GC. Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol. 2007; 36(4):347-351.
• [18]Iemoto Y, Ushigome S, Fukunaga M, Nikaido T, Asanuma K. Case report 679. Central low-grade osteosarcoma with foci of dedifferentiation. Skeletal Radiol. 1991; 20(5):379-382.
• [19]Choong PF, Pritchard DJ, Rock MG, Sim FH, McLeod RA, Unni KK. Low grade central osteogenic sarcoma. A long-term follow-up of 20 patients. Clin Orthop Relat Res. 1996; 322:198-206.
• [20]Rosai J, Ackerman LV. Surgical pathology. 0 Mosby Elsevier, USA; 2011.